Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "breast, cancer" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 37
Tytuł:
Heterogenność raka piersi – sprawozdanie z IMPAKT Breast Cancer Conference
Breast cancer heterogeneity – report from IMPAKT Breast Cancer Conference
Autorzy:
Pogoda, Katarzyna
Powiązania:
https://bibliotekanauki.pl/articles/1066065.pdf
Data publikacji:
2013
Wydawca:
Medical Education
Tematy:
HER2
biopsja przerzutu
heterogenność
mTOR
profile molekularne
Opis:
On 2–4 May 2013, in Brussels took place the 5th IMPAKT conference on translational research in breast cancer. The most important issue raised during the conference was the phenomenon of breast cancer heterogeneity, both inter- and intratumour. Heterogeneity of breast cancer was confirmed at the molecular level, showing the differences in the frequency of genetic aberrations (typically PIK3CA, TP53 and ARID1A) in patients with hormone-dependent advanced breast cancer (BOLERO-2 trial). The results of genetic tests were also presented, which showed that in order to reduce the impact of heterogeneity within the tumor, 3 biopsies should be performed from each breast cancer. The most common disorders of PI3K/mTOR pathway were analyzed depending on the molecular type of breast cancer. However, an attempt to determine by immunohistochemistry biomarkers predicting response to combination therapy with everolimus and trastuzumab failed. The results of two studies, which analyzed the value of molecular tests in predicting late recurrence of breast cancer (in 5–10 years after diagnosis), were presented – the best results were achieved with PAM50 and Breast Cancer Index. The latest discoveries in molecular imaging were also presented – it allows for early assessment of treatment efficacy.
W dniach 2–4 maja 2013 r. w Brukseli odbyła się 5. konferencja IMPAKT poświęcona tematyce badań podstawowych nad rakiem piersi. Najważniejszym zagadnieniem poruszanym podczas konferencji było zjawisko heterogenności raka piersi, występujące zarówno między guzami, jak i w obrębie jednego guza. Potwierdzono heterogenność raka piersi na poziomie molekularnym, wykazując różnice w częstości aberracji genetycznych (najczęściej w obrębie PIK3CA, TP53 i ARID1A) w guzach u chorych na hormonozależnego, zaawansowanego raka piersi (badanie BOLERO-2). Przedstawiono również wyniki badań genetycznych, które wykazały, że aby ograniczyć wpływ heterogenności w obrębie guza, należy wykonywać 3 biopsje z każdego raka piersi. Zbadano najczęstsze zaburzenia szlaku PI3K/mTOR w zależności od typu molekularnego raka piersi. Natomiast próba określenia za pomocą immunohistochemii biomarkerów odpowiedzi na terapię skojarzoną ewerolimusem z trastuzumabem nie powiodła się. Zaprezentowano wyniki dwóch prac naukowych, w których analizowano wartość testów molekularnych w predykcji późnego nawrotu raka piersi (5–10 lat od rozpoznania) – najlepsze wyniki osiągnięto w przypadku PAM50 i Breast Cancer Index. Poza tym przedstawiono najnowsze doniesienia w zakresie obrazowania molekularnego pozwalającego na wczesną ocenę skuteczności stosowanej terapii.
Źródło:
OncoReview; 2013, 3, 2; 110-114
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Fertility and breast cancer
Autorzy:
Kufel-Grabowska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1064776.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
breast cancer during pregnancy
breast cancer in young women
fertility
fertility preservation strategies
Opis:
Breast cancer is the most common cancer among females worldwide. The mean age of breast cancer patients is > 60 yrs old, and it is seldom found in women < 40 yrs old (6.5%) and in very young women < 35 yrs old (0.6%). In young females, fertility and all its aspects are an additional therapeutic challenge. Before initiating treatment, the oncologist should offer effective contraception to be applied throughout the therapy, bearing in mind that fertility preservation is of utmost importance. When it comes to breast cancer in pregnancy, the attending physician should use a therapy which is safe for both the mother and the foetus. Chemotherapy, radiotherapy, hormonal therapy and immunotherapy can, to a lesser or greater degree, damage the ovarian function resulting in amenorrhea in women < 50 yrs (33–76%). However, owing to fertility preservation strategies, more and more pregnancies are successful, even in breast cancer survivors.
Źródło:
OncoReview; 2016, 6, 4; A157-161
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Stomach metastasis from breast cancer-mimicking linitis plastica
Autorzy:
Czerko, Katarzyna
Ostrowski, Michał
Bodnar, Lubomir
Powiązania:
https://bibliotekanauki.pl/articles/3200732.pdf
Data publikacji:
2022-09-30
Wydawca:
Medical Education
Tematy:
breast cancer
gastric metastases
Opis:
We report a rare case of metastatic gastric cancer from invasive carcinoma of the breast (BC) as the first symptom of disease-mimicking primary gastric linitis plastica.
Źródło:
OncoReview; 2022, 12, 3; 65-67
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Off-label drug use in breast cancer therapy
Autorzy:
Jankowski, Tomasz
Urbaniak, Monika
Powiązania:
https://bibliotekanauki.pl/articles/773466.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
breast cancer
capecitabine
chemotherapy
liposomal doxorubicin
metronomic vinorelbine
off-label
Opis:
Breast cancer is one of the most common malignancies across the world, including Poland. Chemotherapy plays an important part in the treatment of the disease. Most of the available chemotherapy drugs and regimens have undergone randomized clinical studies and have been registered for that specific indication. However, a number of drugs are used in an off-label manner, i.e. outside the officially approved product specifications. The paper discusses the use of several off-label therapies in breast cancer in order to demonstrate that such treatment may be well-grounded and indeed turns out beneficial in many cases. It describes the use of liposomal doxorubicin in pre- and post-operative treatment, capecitabine for incomplete efficacy of preoperative treatment, and the administration of metronomic vinorelbine. Moreover, the paper is aimed at demonstrating the legal basis and the principles of marketing authorization of off-label drug use.
Źródło:
OncoReview; 2017, 7, 2; 83-87
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Paraneoplastic neurological syndrome in the course of breast cancer
Autorzy:
Ciszewska, Anna
Głogowski, Łukasz
Witkoś, Andrzej
Rusinowska, Zofia
Nowakowska-Zajdel, Ewa
Powiązania:
https://bibliotekanauki.pl/articles/1065222.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
breast cancer
paraneoplastic neurological syndromes
stiff person syndrome
Opis:
Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases. They have a typically aggressive course, leading to profound and essentially irreversible disability. The pathogenic cause behind PNS is damage of the nervous system structures as a consequence of the body’s immunological reaction induced by cancer. Onconeural antibodies generated as part of the reaction target the tumour tissues, but also the regular nervous tissue recognized as antigens. Presence of onconeural antibodies reveals a 50–60% sensitivity and 100% specificity in diagnosing PNS. Imaging and laboratory tests have a limited impact on diagnosis. What is crucial is the analysis of clinical systems following Graus’s criteria (elaborated in 2004). In the case presented here, the patient underwent treatment in many neurological departments due to the symptoms of progressive damage of the nervous system. She was eventually diagnosed with the stiff person syndrome related to breast cancer. In spite of the treatment, including an efficacious oncological therapy, the severe neurological deficit resulted in serious motor disability.
Źródło:
OncoReview; 2015, 5, 2; A76-80
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Severe aortic stenosis in a patient with breast cancer
Autorzy:
Mańczak, Rafał
Wilk, Michał
Walaszkowska-Czyż, Anna
Florczyk, Michał
Szmit, Sebastian
Powiązania:
https://bibliotekanauki.pl/articles/1064894.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
anthracyclines
aortic stenosis
aortic valve replacement
breast cancer
echocardiography
Opis:
We present a case of 68-year-old female with severe symptomatic aortic stenosis and locally advanced breast cancer disqualified from mastectomy due to heart failure and from aortic valve replacement due to malignant neoplasm. The patient received neoadjuvant chemotherapy without anthracyclines. The aortic valve replacement was performed and then mastectomy and lymphadenectomy were made without hemodynamic complications. Adjuvant hormonotherapy was started. During 42 months of follow-up the patient remained free of recurrent cancer disease as well as no progression of heart failure was observed.
Źródło:
OncoReview; 2016, 6, 2; A49-56
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Anti-breast cancer potential of honey: a narrative review
Autorzy:
Qadirifard, Mohammad Sadegh
Fathabadi, Amirhossein
Hajishah, Hamed
Gholami, Kosar
Abbasi, Mohammadmehdi
Sami, Nafiseh
Zo, Mostafa Mahmoudi
Kadkhodaei, Fateme
Sina, Mahla
Ansari, Arina
Rahimi, Zahra
Deravi, Niloofar
Powiązania:
https://bibliotekanauki.pl/articles/2047807.pdf
Data publikacji:
2022-03-31
Wydawca:
Medical Education
Tematy:
honey
breast cancer
anticancer
complementary medicine
Opis:
Cancer is responsible for the death of millions of people all around the world. Among the large group of cancers, the prevalence of breast cancer is highest in women. Therapeutic interventions, including removal surgery, radiation therapy, hormone therapy, and chemotherapy which is largely used, may cause adverse effects on the quality of patients’ life. This fact has encouraged researchers to find natural substances such as honey to overcome harmful effects. Nowadays, honey is recommended for plenty of abnormalities because of its antioxidant, anti-inflammatory, and antimicrobial properties. Various studies have been conducted to explore the anticancer benefits of different types of honey from different origins. In this review, we are going to summarize in-vitro, animal, and human studies on the anti-breast cancer potential of honey.
Źródło:
OncoReview; 2022, 12, 1; 5-15
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Everolimus with exemestane in elderly breast cancer patients – case report
Autorzy:
Jagiełło-Gruszfeld, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/1065836.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
breast cancer
elderly
everolimus
exemestan
Opis:
Treating elderly patients suffering from metastatic breast cancer still constitutes a significant therapeutic problem. The possibility of administering everolimus in combination with exemestane appears to be a promising therapeutic option in the case of hormone-dependent cancers, without HER2 receptor overexpression.
Źródło:
OncoReview; 2014, 4, 1; A33-36
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The use of fulvestrant in patients with advanced breast cancer
Autorzy:
Kufel-Grabowska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1035843.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
breast cancer
fulvestrant
hormone therapy
Opis:
Breast cancer is the most common malignancy in women in Poland and the entire world, but thanks to early diagnostics and efficacious therapeutic methods, its prognosis is good. In some patients with advanced breast cancer, long-term survival is observed, which is why it is essential to select the most appropriate therapy, and to follow up on the course of disease and possible adverse events related to the treatment applied. The slow development of hormone-receptor-positive cancer, and a multitude of therapeutic options constitute a real challenge in palliative treatment. The use of fulvestrant resulted in a good response in both of the presented cases, and did not in any way comprise the daily lives of the patients over a long period of time.
Źródło:
OncoReview; 2018, 8, 1; 15-18
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The young breast cancer patient therapy – new opportunities, new challenges
Autorzy:
Załuska-Kusz, Joanna
Kufel-Grabowska, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1035689.pdf
Data publikacji:
2019
Wydawca:
Medical Education
Tematy:
breast cancer in young patient
metastatic disease
non-pegylated liposomal doxorubicin
ribociclib
Opis:
The paper describes the case of a 31-year-old female patient with breast cancer with the abdominal metastases. This disease in young people usually has a more aggressive biological subtype, which significantly worsens the prognosis. In this patient aggressive treatment was used. It was effective and did not cause severe or long-term complications.
Źródło:
OncoReview; 2019, 9, 2; 51-54
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Rola eksemestanu w leczeniu raka piersi
Exemestan in breast cancer treatment
Autorzy:
Wójcik, Elżbieta
Powiązania:
https://bibliotekanauki.pl/articles/1067895.pdf
Data publikacji:
2012
Wydawca:
Medical Education
Tematy:
eksemestan
hormonoterapia
inhibitory aromatazy
rak piersi
Opis:
Hormonotherapy is one of the most important therapeutic options in the breast cancer treatment, either locally advanced or metastatic. Tamoxifen has been standard of care for many years, however new clinical trials results indicates aromatase inhibitors as a valuable alternative for postmenopausal patients. Exemestane is a steroid aromatase inhibitor with effectiveness proven in clinical trials discussed in this article.
Leczenie hormonalne jest jedną z podstawowych opcji terapeutycznych w leczeniu raka piersi, zarówno miejscowo zaawansowanego, jak i przerzutowego. Standardem od wielu lat pozostaje tamoksyfen, jednak wyniki nowych badań klinicznych wskazują na inhibitory aromatazy jako na wartościową alternatywę w terapii pacjentek po menopauzie. Eksemestan jest steroidowym inhibitorem aromatazy, którego skuteczność została udowodniona na podstawie wyników badań omówionych w poniższym artykule.
Źródło:
OncoReview; 2012, 2, 4; 264-268
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Efficacy and safety of non-pegylated liposomal doxorubicin in metastatic breast cancer therapy
Autorzy:
Wójcik, Elżbieta
Kufel-Grabowska, Joanna
Gierba-Tomczyk, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1062503.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
breast cancer
non-pegylated liposomal doxorubicin
treatment
Opis:
Breast cancer is the most frequently diagnosed female cancer in Poland (over 17,500 women). Anthracyclines have become one of the most important drugs in breast cancer systemic treatment. In the treatment of metastatic disease combination chemotherapy with doxorubicin provides the objective response rate of 60–85%, and the median time of progression-free survival is about 12 months. Non-pegylated liposomal doxorubicin (NPLD) in combination with cyclophosphamide is associated with a lower risk of cardiotoxicity, higher efficacy and more favourable toxicity profile as compared with conventional anthracycline regimes. Two cases of females patients treated with NPLD described in this article demonstrate the importance of the choice of chemotherapy, professional monitoring, early detection and treatment of adverse effects. Non-pegylated liposomal doxorubicin ordained in systemic treatment of stage IV breast cancer prolongs survival and enhances the quality of life. It is a reasonable option for palliative therapy.
Źródło:
OncoReview; 2017, 7, 4; 162-167
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer - diagnostic difficulties
Autorzy:
Skwierawska, Kamila
Woźniak, Krzysztof
Waszczuk-Gajda, Anna
Drozd-Sokołowska, Joanna
Kacprzyk, Piotr
Chehab, Marita Rachid
Boguradzki, Piotr
Jędrzejczak, Wiesław Wiktor
Basak, Grzegorz Władysław
Powiązania:
https://bibliotekanauki.pl/articles/2032969.pdf
Data publikacji:
2020-12-31
Wydawca:
Medical Education
Tematy:
cancer-related microangiopathic hemolytic anemia
CR-MAHA
breast cancer
thrombotic microangiopathy
thrombocytopenia
Opis:
Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.
Źródło:
OncoReview; 2020, 10, 4; 134-138
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Autorzy:
Streb, Joanna
Słowik, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/1065206.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
breast cancer
cardiotoxicity
liposomal doxorubicin
Opis:
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.
Źródło:
OncoReview; 2015, 5, 2; A67-70
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 37

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies